Abstract
Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 8-11 |
| Number of pages | 4 |
| Journal | European Journal of Cancer |
| Volume | 45 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2009 |
Fingerprint
Keywords
- Anaemia
- Erythropoietin
- Evidence-based practice guidelines
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome : Initial evidence from the RESPOND study. / Aapro, Matti; Van Erps, Joanna; MacDonald, Karen; Soubeyran, Pierre; Muenzberg, Michael; Turner, Matthew; Warrinnier, Hans; Albrecht, Tara; Abraham, Ivo L.
In: European Journal of Cancer, Vol. 45, No. 1, 01.2009, p. 8-11.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome
T2 - Initial evidence from the RESPOND study
AU - Aapro, Matti
AU - Van Erps, Joanna
AU - MacDonald, Karen
AU - Soubeyran, Pierre
AU - Muenzberg, Michael
AU - Turner, Matthew
AU - Warrinnier, Hans
AU - Albrecht, Tara
AU - Abraham, Ivo L
PY - 2009/1
Y1 - 2009/1
N2 - Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.
AB - Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.
KW - Anaemia
KW - Erythropoietin
KW - Evidence-based practice guidelines
UR - http://www.scopus.com/inward/record.url?scp=57749201142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57749201142&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2008.09.036
DO - 10.1016/j.ejca.2008.09.036
M3 - Article
C2 - 19058959
AN - SCOPUS:57749201142
VL - 45
SP - 8
EP - 11
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 1
ER -